Is Dr. Dilara a Hit or Flop? Official Box Office Record & Profit Analysis

Detailed Financial Report

Marking its arrival in 2016, Dr. Dilara positioned itself as a Thriller / Drama film aiming for mass appeal. The production path for this project involved significant capital, with a reported budget of approximately $100.0K. In the modern film economy, recovering such an investment requires a multifaceted theatrical strategy spanning domestic and international territories.

Collection Trajectory

The box office journey for Dr. Dilara has culminated in a worldwide gross of approximately $60.0K. This figure represents the total theatrical footprint, reflecting a Return on Investment (ROI) of -40%. The collection trajectory points to a challenging market response, where the theatrical gross struggled to clear the traditional break-even multiplier required for production and marketing recovery.

Profitability & Verdict

Analyzing the multiplier effect and market sentiment, Dr. Dilara navigated the competitive landscape with an audience reception score of 0/10. When weighing the production costs against the global returns, Dr. Dilara is effectively categorized as a Disaster. It serves as an analytical benchmark for the complexities of modern theatrical distribution and evolving viewer preferences.

Comparables

In the context of other Thriller releases, the performance of Dr. Dilara will likely influence how studios approach similar projects in the future. Whether through its innovative visual style or its narrative choices, the film's financial footprint remains a key piece of the 2016 box office narrative.